These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29528251)

  • 61. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Li D; Sabato PE; Guiastrennec B; Ouerdani A; Feng HP; Duval V; De Anda CS; Sears PS; Chou MZ; Hardalo C; Broyde N; Rizk ML
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0089521. PubMed ID: 34516243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
    Li R; Nailor MD
    Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.
    Kennedy G; Osborn J; Flanagan S; Alsayed N; Bertolami S
    Drugs R D; 2015 Dec; 15(4):329-33. PubMed ID: 26416654
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Bassetti M; Hooper D; Tillotson G
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S233-S240. PubMed ID: 30957169
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The safety of treatment options for acute bacterial skin and skin structure infections.
    Bassetti M; Peghin M; Castaldo N; Giacobbe DR
    Expert Opin Drug Saf; 2019 Aug; 18(8):635-650. PubMed ID: 31106600
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.
    Cattaneo D; Alffenaar JW; Neely M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An evaluation of tedizolid for the treatment of MRSA infections.
    Hall RG; Smith WJ; Putnam WC; Pass SE
    Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
    Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.
    Craft JC; Moriarty SR; Clark K; Scott D; Degenhardt TP; Still JG; Corey GR; Das A; Fernandes P
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S520-6. PubMed ID: 21546629
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two new drugs for skin and skin structure infections.
    Med Lett Drugs Ther; 2014 Aug; 56(1449):73-5. PubMed ID: 25118799
    [No Abstract]   [Full Text] [Related]  

  • 72. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.
    Powers JH; Das AF; De Anda C; Prokocimer P
    Contemp Clin Trials; 2016 Sep; 50():265-72. PubMed ID: 27530088
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antimicrobial and immunomodulatory effects of tedizolid against methicillin-resistant Staphylococcus aureus in a murine model of hematogenous pulmonary infection.
    Kaku N; Morinaga Y; Takeda K; Kosai K; Uno N; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
    Int J Med Microbiol; 2016 Sep; 306(6):421-8. PubMed ID: 27259840
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.
    Park AYJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914949
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
    Hussar DA; Nguyen A
    J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
    [No Abstract]   [Full Text] [Related]  

  • 76. Comparison of digital planimetry and ruler technique to measure ABSSSI lesion sizes in the ESTABLISH-1 study.
    Bien P; De Anda C; Prokocimer P
    Surg Infect (Larchmt); 2014 Apr; 15(2):105-10. PubMed ID: 24450727
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thrombocytopenia with Tedizolid and Linezolid.
    Lee EY; Caffrey AR
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
    [TBL] [Abstract][Full Text] [Related]  

  • 79. What's new in the treatment of serious MRSA infection?
    Holmes NE; Howden BP
    Curr Opin Infect Dis; 2014 Dec; 27(6):471-8. PubMed ID: 25211361
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
    Ong V; Flanagan S; Fang E; Dreskin HJ; Locke JB; Bartizal K; Prokocimer P
    Drug Metab Dispos; 2014 Aug; 42(8):1275-84. PubMed ID: 24875463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.